Rallybio Book Value per Share

What does Rallybio do? Rallybio Corp. generates revenue by identifying, researching, and developing clinical biotechnology products and therapies for severe and rare diseases. The firm focuses on accelerating the development of life-transforming therapies, with a specific program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare hematological disease affecting fetuses and newborns. The company's pipeline includes several candidates such as RLYB212, a subcutaneously administered human monoclonal anti-HPA-1a antibody candidate for preventing HPA-1a maternal alloimmunization and FNAIT occurrence. Additionally, the advanced product candidate RLYB116 serves as an inhibitor of complement component 5 (C5) to treat complement dysregulation conditions including paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). The pipeline also features RLYB114, a pegylated C5-targeted Affibody molecule, and the ENPP1 Program, alongside RLYB331, targeting patients with these specific medical needs. Rallybio is one of the most popular companies on Eulerpool.